Ani Pharmaceuticals Inc

Health Care
Biotechnology: Pharmaceutical Preparations
www.anipharmaceuticals.com

Earnings Score
Moat Score
Safety Score

Market Cap $1.36B
PE -68
Debt $318.28M
Cash $144.89M
EV $1.54B
FCF $47.78M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$20.15M
EBIT	$584.00K
ROE	-5%
ROA	0%
FCF	$47.78M
Equity	$403.68M
Growth Stability	-334%
PE	-67.71
PEG	-129.55
PB	3.38
P/FCF	28.55
P/S	2.22
Price/Cash	0.11
Debt/Equity	0.79
Debt/FCF	6.66
Net Margins	-3%
Gross Margins	59%
Op. Margins	0%
Earnings CAGR	5%
Sales Growth YoY	45%
Sales Growth QoQ	28%
Sales CAGR	18%
FCF CAGR	4%
Equity CAGR	12%
Earnings Stability	0.02
Earnings Growth YoY	-2K%
Earnings Growth QoQ	-57%
Earnings CAGR 5Y	1%

Sales CAGR 5Y	31%
FCF CAGR 5Y	31%
Equity CAGR 5Y	23%
Earnings CAGR 3Y	44%
Sales CAGR 3Y	44%
FCF CAGR 3Y	18%
Equity CAGR 3Y	16%
Market Cap	$1.36B
Revenue	$614.38M
Dividend Yield	0%
Payout Ratio	-8%
Assets	$1.28B
Total Debt	$318.28M
Cash	$144.89M
Shares Outstanding	19.32M
EV	1.54B
Earnings Score	6%
Moat Score	12%
Safety Score	50%
Final Score	23%
Working Capital	334M
Current Ratio	2.72
Gross Profit	$364.17M
Shares Growth 3y	9%
Equity Growth QoQ	-1%
Equity Growth YoY	-7%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Propafenone, and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

SEC Filings

Direct access to Ani Pharmaceuticals Inc (ANIP) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Ani Pharmaceuticals Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Ani Pharmaceuticals Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 5%

Stability 2%

loading chart...

Ani Pharmaceuticals Inc Discounted Cash Flow

Fully customizable DCF calculator online for Ani Pharmaceuticals Inc.

Years

Calculation mode

= $625M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$48M	$50M	$52M	$54M	$56M	$58M	$60M	$63M	$65M	$68M	$70M	$702M
DCF		$45M	$43M	$40M	$38M	$36M	$34M	$32M	$30M	$29M	$27M	$271M
Value	$625M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	20%	3%	-1%	8%	3%	-11%	-20%	-16%	4%	-3%	-3%
ROA	-	6%	7%	8%	4%	-3%	-5%	-5%	5%	0%	0%
ROE	-	2%	-1%	8%	3%	-12%	-13%	-16%	4%	-5%	-5%

Bad Net Margins (-3.28%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	6.28	5.06	2.93	4.76	20.33	375.65	-7.15	2.59	6.66	6.66
Debt over Equity	0.9	0.85	0.84	0.91	0.87	0.95	0.86	0.91	0.66	0.79	0.79
Growth Stability	-	-	-	100%	99%	-334%	-	-	-	-	-334%

Bad Debt/FCF ratio (6.66)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Good Debt/Equity ratio (0.79)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (-334%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	69%	37%	14%	2%	1%	4%	46%	54%	26%	31%
Earnings YoY growth	-	-74%	-127%	-2K%	-61%	-476%	90%	16%	-135%	-217%	1%
Equity YoY growth	-	6%	3%	13%	8%	-8%	71%	-6%	38%	-7%	23%
FCF YoY growth	-	52%	27%	111%	-36%	-77%	-92%	-5K%	-375%	-57%	31%